Mikronährstoffe während der Krebstherapie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Je nach Tumorentität und Geschlecht supplementieren bis zu 90 % der Krebspatienten antioxidative und immunstabilisierende Vitamine und andere Mikronährstoffe, häufig ohne das Wissen der behandelnden Ärzte. Von onkologischer Seite bestehen berechtigte Bedenken, dass Nahrungsergänzungsmittel die Wirksamkeit einer Chemo- oder Strahlentherapie beeinträchtigen könnten. Aktuelle Studien liefern jedoch zunehmend Hinweise darauf, dass durch eine medikationsorientierte Supplementierung von Mikronährstoffen wie Selen, L-Carnitin und Vitamin D die Verträglichkeit von Tumortherapien sowie die Compliance der Patienten verbessert und die Rate an Therapieabbrüchen vermindert werden kann. Dadurch könnte das Ansprechen auf die antineoplastischen Verfahren erhöht sowie die Prognose und die Lebensqualität der Patienten verbessert werden. Onkologisch tätige Ärzte sollten daher über die Bedeutung von Mikronährstoffen und potenzielle Interaktionen mit der Krebstherapie informiert sein.

Summary

Many patients receiving cancer treatment use micronutrient supplements, with the intention to complement their cancer treatment, or help them cope with the therapy- and disease-associated side-effects. Up to 90 % of the cancer patients are adding antioxidants without the knowledge of the treating physician. There are many concerns that antioxidants might decrease the effectiveness of chemotherapy, but increasing evidence suggests a benefit when antioxidants and other micronutrients, such as selenium, L-carnitine and vitamin D are added to conventional cytotoxic therapies. It is imperative that physicians discuss the use of antioxidant and other micronutrient supplements with their cancer patients and educate them about potentially negative, but also potentially beneficial effects.

• Literatur

• 1 Asfour IA, El-Tehewi MM, Ahmed MH et al High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin’s lymphoma. Biol Trace Elem Res 2009; 127(3): 200-210
  CrossrefPubMedGoogle Scholar
• 2 Asfour IA, Fayek M, Raouf S et al The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin’s lymphoma patients: correlation with response and survival. Biol Trace Elem Res 2007; 120(1−3): 1-10
  CrossrefPubMedGoogle Scholar
• 3 Bedogni A, Saia G, Bettini G et al Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?. Oncologist 2012; 17(8) 1114−1119
  PubMedGoogle Scholar
• 4 Bianchi G, Vitali G, Caraceni A et al Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41(12): 1746-1750
  CrossrefPubMedGoogle Scholar
• 5 Block KI, Koch AC, Mead MN et al Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123(6): 1227-1239
  CrossrefPubMedGoogle Scholar
• 6 Büntzel J, Riesenbeck D, Glatzel M et al Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res 2010; 30(5): 1829-1832
  PubMedGoogle Scholar
• 7 Chen, Q. Espey MG, Sun AY et al Pharmacologic doses of ascorbate act as prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105 (32): 11037-11038
  CrossrefPubMedGoogle Scholar
• 8 Chen Q, Espey MG, Krishna MC et al Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as prodrug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102(38): 13604-13609
  CrossrefPubMedGoogle Scholar
• 9 D’Andrea G. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55(5): 319-321
  CrossrefPubMedGoogle Scholar
• 10 De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007; 21(Suppl1): 39-43
  CrossrefPubMedGoogle Scholar
• 11 Drake MT, Maurer MJ, Link BK, Habermann TM et al Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28: 4191-4198
  CrossrefPubMedGoogle Scholar
• 12 Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003; 22(2) 118−123.
  PubMedGoogle Scholar
• 13 Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363(21): 2027-2035
  CrossrefPubMedGoogle Scholar
• 14 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29(4): 81-82
  CrossrefPubMedGoogle Scholar
• 15 Goodwin PJ, Ennis M, Pritchard KI, Koo J et al Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-63
  CrossrefPubMedGoogle Scholar
• 16 Gröber U, Holzhauer P, Kisters K. Besser durch die Krebstherapie. Mehr Lebensqualität mit den richtigen Vitaminen und Mineralstoffen. 1. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
  Google Scholar
• 17 Gröber U, Mücke R, Adamietz I et al Komplementärer Einsatz von Antioxidanzien und Mikronährstoffen in der Onkologie - Update 2013. Der Onkologe 2013; 19(2): 136-143
  CrossrefPubMedGoogle Scholar
• 18 Gröber U, Spitz J, Reichrath J, Kisters K, Holick MF. Vitamin D. Update 2013. From rickets prophylaxis to general healthcare. Dermatoendocrinol 2013; 5(3): 331-347
  CrossrefPubMedGoogle Scholar
• 19 Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol 2012; 4(2): 158-166
  CrossrefPubMedGoogle Scholar
• 20 Gröber U. Vitamin C in der komplementären Onkologie. Medizinische Monatsschrift für Pharmazeuten 2009; 32: 263-267
  PubMedGoogle Scholar
• 21 Gröber U. Vitamin-C-Hochdosisinfusionstherapie beim Mammakarzinom. Dtsch Z Onkol 2007; 39 (2): 80-81
  PubMedGoogle Scholar
• 22 Hu YJ, Chen Y, Zhang YQ et al The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997; 56(3): 331-341
  CrossrefPubMedGoogle Scholar
• 23 Jin HW, Flatters SJ, Xiao WH et al Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210(1): 229-237
  CrossrefPubMedGoogle Scholar
• 24 Khan QJ et al Randomized trail of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial. J Clin Oncol 2012; 30(Suppl): abstr. 9000, ASCO-Kongress 2012
  PubMedGoogle Scholar
• 25 Khan QJ, Reddy PS, Kimler BF, Sharma P et al Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119(1): 111-118
  CrossrefPubMedGoogle Scholar
• 26 Kraft M, Kraft K, Gärtner S et al L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) − a randomized multicentre trial. Nutr J 2012; 11: 52 DOI: doi: 10.1186/1475-2891-11-52.
  CrossrefPubMedGoogle Scholar
• 27 Ma Y, Chapman J, Levine M et al High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014; 6(222) 222ra18
  PubMedGoogle Scholar
• 28 Mohr SB, Gorham ED, Kim J et al Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res 2014; 34(3): 1163-1166
  PubMedGoogle Scholar
• 29 Mücke R, Schomburg L, Gröber U, Holzhauer P, Micke O. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe 2010; 16: 181-186
  CrossrefPubMedGoogle Scholar
• 30 Mücke R, Schomburg L, Glatzel M et al Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010; 78(3): 828-835
  CrossrefPubMedGoogle Scholar
• 31 Nechuta S, Lu W, Chen Z et al Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20(2): 262-271
  CrossrefPubMedGoogle Scholar
• 32 Padayatty JS, Riordan HD, Hewitt SM et al Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174(7): 937-942
  CrossrefPubMedGoogle Scholar
• 33 Padayatty JS, Sun H, Wang Y et al Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 2004; 140(7): 533-538
  CrossrefPubMedGoogle Scholar
• 34 Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK et al Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 2011; 125(3): 869-78
  CrossrefPubMedGoogle Scholar
• 35 Santini D, Galluzzo S, Vincenzi B, Zoccoli A et al Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21: 185-186
  CrossrefPubMedGoogle Scholar
• 36 Sayed-Ahmed MM, Salman TM, Gaballah HE et al Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol Res 2001; 43(6): 513-520
  CrossrefPubMedGoogle Scholar
• 37 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 2004; 93(2): 320-327
  CrossrefPubMedGoogle Scholar
• 38 Vollbracht C, Schneider B, Leendert V, Weiss G et al Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and after care: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 25: 983-990
  PubMedGoogle Scholar
• 39 Wallenberg M, Misra S, Björnstedt M. Selenium cytotoxicity in cancer. Basic Clin Pharmacol Toxicol 2014; 114(5): 377-386 Epub ahead of print
  CrossrefPubMedGoogle Scholar
• 40 Welsh JL, Wagner BA. Van’t Erve TJ et al Pharmacological ascorbate with gemcitabine for the control of metastastic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71(3): 765-775
  CrossrefPubMedGoogle Scholar
• 41 Wenzel U, Nickel A, Daniel H. Increased carnitine-dependent fatty acid uptake into mitochondria of human colon cancer cells induces apoptosis. J Nutr 2005; 135(6): 1510-1514
  PubMedGoogle Scholar